08

November

2023

|

07:29 AM

Europe/Amsterdam

Bayer Group:

Summary

Team product sales of 10.342 billion euros (Forex & portfolio adj. minus 0.2 per cent) / EBITDA right before unique things: one.685 billion euros (minus 31.3 percent) / Sales secure at Crop Science and Prescribed drugs and up somewhat at Consumer Health (Fx & portfolio adj.) / Earnings decreased at all divisions, particularly Crop Science / Core earnings for every share at .38 euros (minus 66.4 percent) / Web income at minus 4.569 billion euros, impacted by impairment losses at Crop Science due to fascination premiums / Free of charge money stream at 1.626 billion euros / CEO Anderson: “We are redesigning Bayer to focus only on what is crucial for our mission, ‘Health for all, starvation for none’” / Structural possibilities remain beneath critique